ASLN vs. AIMD, KA, PULM, TENX, HILS, ENVB, SHPH, IBIO, RNAZ, and PCSA
Should you be buying ASLAN Pharmaceuticals stock or one of its competitors? The main competitors of ASLAN Pharmaceuticals include Ainos (AIMD), Kineta (KA), Pulmatrix (PULM), Tenax Therapeutics (TENX), Hillstream BioPharma (HILS), Enveric Biosciences (ENVB), Shuttle Pharmaceuticals (SHPH), iBio (IBIO), TransCode Therapeutics (RNAZ), and Processa Pharmaceuticals (PCSA). These companies are all part of the "pharmaceutical preparations" industry.
ASLAN Pharmaceuticals (NASDAQ:ASLN) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations.
In the previous week, ASLAN Pharmaceuticals had 2 more articles in the media than Ainos. MarketBeat recorded 7 mentions for ASLAN Pharmaceuticals and 5 mentions for Ainos. Ainos' average media sentiment score of 1.10 beat ASLAN Pharmaceuticals' score of 0.38 indicating that Ainos is being referred to more favorably in the news media.
Ainos has lower revenue, but higher earnings than ASLAN Pharmaceuticals. Ainos is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by company insiders. Comparatively, 4.6% of Ainos shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
ASLAN Pharmaceuticals received 200 more outperform votes than Ainos when rated by MarketBeat users.
ASLAN Pharmaceuticals currently has a consensus target price of $11.33, suggesting a potential upside of 2,657.50%. Given ASLAN Pharmaceuticals' higher possible upside, equities analysts clearly believe ASLAN Pharmaceuticals is more favorable than Ainos.
ASLAN Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Ainos has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.
ASLAN Pharmaceuticals has a net margin of 0.00% compared to Ainos' net margin of -11,205.49%. Ainos' return on equity of -47.96% beat ASLAN Pharmaceuticals' return on equity.
Summary
ASLAN Pharmaceuticals beats Ainos on 10 of the 16 factors compared between the two stocks.
Get ASLAN Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ASLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ASLAN Pharmaceuticals Competitors List
Related Companies and Tools
